Current perspective on the use of angiotensin-converting enzyme inhibitors in the management of coronary (atherosclerotic) artery disease

Annals of Pharmacotherapy

Volumn 31, Issue 12, 1997, Pages 1499-1506

  Cheng, Judy W M ^a,b   Ngo, Mimi N ^c  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Arnold Marie Schwartz Coll P

Author keywords

Angiotensin converting enzyme inbibitors; Atherosclerosis; Renin angiotension system

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; LISINOPRIL; PRAVASTATIN; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ATHEROGENESIS; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG EFFICACY; FIBRINOLYSIS; GROWTH INHIBITION; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0031465963     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101210     Document Type: Review

References (43)

1. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
2. Sytkowski PA, Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. Circulation 1996;93:697-703.
3. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984;144:1947-53.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35.
5. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
7. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
8. Eselin JA, Carter BL. Hypertension and left ventricular hypertrophy: is drug therapy beneficial? Pharmacotherapy 1994;14:60-88.
9. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
10. Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton G, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischemia in chronic stable angina. Br Heart J 1989;62:112-7.
11. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-8.
12. Basha BJ, Sowers JR. Atherosclerosis: an update. Am Heart J 1995;131: 1192-202.
13. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-62.
14. Chobanian AV. Pathophysiology of atherosclerosis. Am J Cardiol 1992; 70(27):3G-7G.
15. Greenwald L, Becker RC. Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. Am Heart J 1994;128:997-1009.
16. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertension 1993:11(suppl 3):S13-8.
17. Graras H. Angiotensin-converting enzyme inhibition and the heart. Circulation 1994;23:813-8.
18. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987;79:1-6.
19. Van Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. Circulation 1994;89: 458-70.
20. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman SL, et al. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet 1993;342: 1073-5.
21. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
22. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993;22(suppl 5):S1-9.
23. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 1994;89:493-8.
24. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis. Circulation 1996;93:848-52.
25. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
26. Vanhoutte PM, Boulanger CM, Mambouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995;76: 3E-12E.
27. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
28. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth-factor A chain and cc-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-24.
29. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342: 821-8.
30. Pfeiffer MA, Braunwald E, Moye LA, Basta LB, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327: 669-77.
31. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Micardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
32. ISIS-4. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
33. Chinese Cardiac Study Collaborate Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345: 686-7.
34. The Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992;86:100-10.
35. Faxon DP, for the MARCATOR Study Group. Effects of high dose angiotensin-converting-enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double blind, placebo controlled trial of cilazapril. J Am Coll Cardiol 1995;2:362-9.
36. Dusting GJ, Hyland R, Hickey H, Makdissi M. Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries. Am J Cardiol 1995;76: 24E-7E.
37. Chobanian AV, Hauderschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
38. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis. Circulation 1996;93:848-52.
39. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Ann Intern Med 1996;156:1952-6.
40. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996;27:1048-52.
41. Cashin-Hemphill L, Dinsmore RE, Chan RC, Williams SN, Holmvang G, Haber HE, for the QUIET investigators. Atherosclerosis progression in subjects with and without post-angioplasty restenosis in QUIET (abstract). J Am Coll Cardiol 1997;29:418A.
42. Abbey M, Nestel PJ, Baghurst PA. Antioxidant vitamins and low-density-lipoprotein oxidation. Am J Clin Nutr 1993;58:525-32.
43. Wright JT, for the ALLHAT Research Group. The Antihypertensive and Lipid Lowering Heart Attack Trial (abstract). Am J Hypertens 1995;8(4 part 2):27A.